Our Science
The AcuamarkDx Solution:
Multiplexed. Automated.
High Throughput.
How We’re Solving for the Key Challenge Early Stage Cancer Diagnostics Face
No existing or developmental stage cancer test is both sensitive and specific at early stages—where signal is low in abundance, like in early cancers.
Our team is the pioneer in optimizing qPCR for the detection of low-abundance methylation markers and mid-level multiplexing. This approach is more suitable for disease detection compared to the prevailing low-level or ultra-high-level multiplexing methods in the industry.
How We’re Solving for the Key Challenge Early Stage Cancer Diagnostics Face
No existing or developmental stage cancer test is both sensitive and specific at early stages—where signal is low in abundance, like in early cancers.
Our team is the pioneer in optimizing qPCR for the detection of low-abundance methylation markers and mid-level multiplexing. This approach is more suitable for disease detection compared to the prevailing low-level or ultra-high-level multiplexing methods in the industry.
Asymptomatic Monitoring
Richly Nuanced, Semi-Quantitative Detection of Low Abundance Cancer Methylation Signal in Blood
qPCR
Proprietary, broadly multiplexed, 2-step PCR amplifies methylated DNA signal while preventing noise.
Automated
Ultra-scalable and cost-effective, either via central (lab) or sited distribution. Rapid. High throughput.
2-Steps
Samples are screened twice to double verify and analyze suspicious signal for greater accuracy.
dPCR
Whole new level of sophisticated, multi-dimensional, dPCR readout (proprietary).
Predictive Models
Sophisticated predictive ML models are used to distinguish cancer-specific from normal methylation.
Cost-Effective, Seamless Clinical Workflow
Blood Sample
Blood sample is ordered by primary care provider.
Blood-Based Screening
Sample is sent to any clinical lab and abnormal results are screened again.
Early, Targeted Cancer Care
Results are shared with patient’s general practitioner and referred to an appropriate cancer specialist helping patients receive early-targeted treatment and higher survival rates.
Unique 2-Step Process for Greater Accuracy
1,000 Patients Screened at Annual Check-up
Step 1- Novel Assay
- Screen with EAGLE i5 real-time PCR assay
- 950 patients are eliminated
- Identifies 50 suspected positives for Step 2
Step 2 - Novel Assay
- Using the same blood sample another test is performed with the remaining 50 suspected positives with EAGLE i5 real-time PCR assay
- 35 are eliminated, but should re-test in 6 months
- 15 are sent back to GP and/or specialist(s) for follow up with NGS and other technologies
Publications
May 2020
Application of Multiplex Bisulfite PCR–Ligase Detection Reaction–Real-Time Quantitative PCR Assay in Interrogating Bioinformatically Identified, Blood-Based Methylation Markers for Colorectal Cancer
January 2020
Prediction of Blood-based Biomarkers and Subsequent Design of Bisulfite PCR-LDR-qPCR Assay for Breast Cancer Detection
May 2020
Application of Multiplex Bisulfite PCR–Ligase Detection Reaction–Real-Time Quantitative PCR Assay in Interrogating Bioinformatically Identified, Blood-Based Methylation Markers for Colorectal Cancer
December 2017
